In 2022 the company made a revenue of N/A a decrease over the years 2021 revenue that were of N/A.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | N/A | |
2022 | N/A | |
2021 | N/A | |
2020 | N/A | |
2019 | N/A | |
2018 | N/A | |
2017 | N/A | |
2016 | N/A | -100% |
2015 | $0.46 M | 511.06% |
2014 | $0.07 M | 53.57% |
2013 | $0.05 M | 0% |
2012 | $0.05 M | 166.67% |
2011 | $0.01 M | |
2010 | N/A | |
2009 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | N/A | ๐บ๐ธ USA |
Pfizer PFE | $58.49 B | N/A | ๐บ๐ธ USA |
Abbott Laboratories ABT | $40.10 B | N/A | ๐บ๐ธ USA |
Regeneron Pharmaceuticals REGN | $13.11 B | N/A | ๐บ๐ธ USA |
Rigel Pharmaceuticals RIGL | $0.11 B | N/A | ๐บ๐ธ USA |
Flexion Therapeutics
FLXN | $0.10 B | N/A | ๐บ๐ธ USA |
Aerie Pharmaceuticals AERI | $0.21 B | N/A | ๐บ๐ธ USA |